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Abstract
Knowledge about the genetics of primary torsion dystonia (PTD) has been progressing at a very slow
pace compared with other movement disorders. For many years, only one causative gene was
known, DYT1/TOR1A, yet the recent identification of a second PTD causative gene (DYT6/THAP1),
the detection of subclinical alterations caused by mutations in PTD genes in some healthy non-
penetrant individuals, and functional studies on TOR1A and THAP1 protein products have significantly
improved mutation detection, genotype-phenotype correlates, and our understanding of the cellular
mechanisms underlying the development of dystonia.
Introduction and context
Torsion dystonias are characterized by involuntary muscle
contractions that result in repetitive movements and
abnormal postures. The term ‘primary torsion dystonia’
(PTD) usually refers to pure primary forms characterized
bydystoniaalone[1](Table1),yet thistermhasalsobeen
employed with a more extensive meaning to describe all
forms of primary dystonias, although such usage is
discouraged [2]. Pure PTD (hereafter referred to simply
as PTD) can be further divided based on the age of onset
(early onset being variably defined as beginning between
the ages of 20 and 30 years) and distribution of dystonia
(which can be focal, segmental, or generalized). Familial
aggregation is more common in early-onset forms, which
also present a higher propensity to generalize, whereas
late-onset PTD is often sporadic and tends to remain focal
or segmental in distribution [1,3].
For several years, only one gene causative of autosomal
dominant PTD has been known: the DYT1/TOR1A
gene [4]. DYT1 dystonia is caused in nearly all cases by a
G A Gd e l e t i o ni ne x o n5o fTOR1A and is typically
characterized by early onset in a limb, generalization,
and a tendency to spare the cranial-cervical muscles
[5,6]. There is markedly reduced penetrance (only 30%
of mutation carriers actually develop the disease in their
life) and wide phenotypic variability even within
families; atypical phenotypes, including late-onset,
focal, or segmental dystonia phenotypes with cranial-
cervical involvement, have been reported [7,8].
Major recent advances
The DYT6/THAP1 gene
In 2009, Fuchs and colleagues [9] identified THAP1
(thanatos-associated protein domain-containing apop-
tosis-associated protein 1) as the second gene causative
of autosomal dominant PTD. The THAP1 gene encodes
a protein characterized by a conserved putative DNA-
binding motif, a proline-rich region, and a large coiled-
coil region that includes a nuclear localization domain.
Deleterious mutations were first identified in four
ancestrally related Amish-Mennonite families and in a
fifth, unrelated family of German ancestry. Subse-
quently, THAP1 heterozygous mutations were identi-
fied in 9 out of 36 (25%) DYT1-negative families with
early-onset non-focal PTD [10]. This high mutation
frequency was not confirmed by other studies that
reported an overall prevalence of about 1.0-2.5% in
PTD cohorts variably selected on the basis of family
history, early onset, generalization, or involvement of
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THAP1 phenotype typically presents with early-onset
dystonia that differs from DYT1 dystonia in the
frequent involvement of the cranial-cervical district.
In particular, speech is commonly affected because of
oro-mandibular dystonia or laryngeal dystonia (or
both). Interestingly, THAP1 was recently found
mutated also in sporadic cases with focal or segmental
dystonia involving the cervical or laryngeal district that
started in the patients’ fifth or sixth decade, suggesting
that this gene may also play a role in the pathogenesis
of late-onset, focal/segmental PTD [14,15]. As for
DYT1/TOR1A, THAP1 mutations are also associated
with reduced penetrance, with healthy mutation
carriers identified in several families.
Tackling PTD complexity: in pursuit of penetrance
modifiers and endophenotypes
The low penetrance and variable phenotypic expression
associated with mutations in DYT1 and DYT6 genes
represent the complexity of PTD genetics well, calling for
the identification of genetic modifiers even in these
monogenic forms. Among the most common forms of
late-onset focal or segmental dystonia, clinical examina-
tion of first-degree relatives detected a positive family
history in up to 25% of patients [16]. These findings
support the hypothesis that PTD represents a truly
complex disorder in which several genetic variants of
low penetrance variably co-occur with environmental
factors that affect the development and phenotypic
manifestation of the disease.
In search of penetrance modifiers in DYT1 dystonia, a
large study on a cohort of American subjects carrying
the pathogenic GAG deletion showed that the fre-
quency of the TOR1A coding variant D216H in trans
with the deletion (e.g., on the other allele) was
increased in healthy mutation carriers and decreased
in affected subjects compared with controls, suggesting
a relevant role for this variant in regulating penetrance
of DYT1-PTD [17]. Two subsequent studies on German-
Italian and French DYT1 mutation carriers, respectively,
gave rise to contrasting results, the first one supporting
and the second arguing against the original findings
[18,19]. At present, the role of this variant requires
confirmation, and the mechanisms underlying reduced
penetrance of DYT1 and DYT6 mutations remain to be
understood.
In this scenario, the identification of novel disease-
associated genes is hampered by the scarcity of large
families with several affected members and the difficulty
to pool homogeneous families for linkage purposes or
groups of patients for association studies.
An interesting approach to overcome these limitations
is the identification of endophenotypes, which are
subclinical traits related to a specific genetic back-
ground (i.e., a pathogenetic mutation in a PTD gene)
detectable also in healthy individuals who are non-
penetrant carriers of the mutation. Indeed, several
studies have reported the presence of subclinical
abnormalities in healthy carriers of DYT1 or DYT6
mutations by neuroimaging (positron emission tomo-
graphy, voxel-based morphometry, diffusion tensor
magnetic resonance imaging) [20,21], neurophysiolo-
gical (cortical and spinal inhibition, temporal discri-
mination, body movement representation) [22-24],
and expression profiling approaches [25]. In light of
these findings, similar approaches have been employed
to detect possible endophenotypes among healthy
relatives of patients with familiar forms of focal
dystonia, in which the major causative gene is still
unknown. In particular, a recent study correlated an
altered temporal discrimination threshold detected in
some healthy family members of dystonic patients
with structural putaminal abnormalities detected by
voxel-based morphometry, supporting the usefulness
of this endophenotypic trait and its potential relevance
in genetic studies [26].
Future directions
Given that the first PTD gene was discovered in 1997
[4], the identification of new dystonia genes has
Table 1. Primary pure dystonia genes/loci according to the DYT nomenclature
Disease (OMIM) Gene/locus Phenotype Transmission
DYT1 (128100) TOR1A Generalized early-limb-onset dystonia AD
DYT2 (224500) Unknown Early-onset generalized dystonia with prominent cranial-cervical involvement AR
DYT4 (128101) Unknown Whispering dysphonia AD
DYT6 (602629) THAP1 Generalized cervical and upper-limb-onset dystonia AD
DYT7 (602124) 18p Adult-onset cervical dystonia AD
DYT13 (607671) 1p36.13-36.32 Cervical and upper-limb dystonia AD
DYT17 (612406) 20p11.2-q13.12 Segmental or generalized dystonia with prominent dysphonia AR
AD, autosomal dominant; AR, autosomal recessive; OMIM, Online Mendelian Inheritance in Man [32].
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ments in the field of non-primary dystonias and other
movement disorders (such as Parkinson disease). The
TOR1A protein product, TorsinA, is a member of the
AAA1 superfamily of ATPases associated with a variety
of cellular activities. This superfamily of chaperone
proteins performs critical functions related to protein
degradation, membrane trafficking, vesicle fusion and
organelle movement,cytoskeletal dynamics, and correct
folding of proteins [27,28]. TorsinA is almost ubiqui-
tously expressed, and its expression in the brain is
restricted to neurons, where it is associated with the
endoplasmic reticulum (ER). In cellular models expres-
sing the pathogenic GAG deletion, mutant TorsinA is
r e d i s t r i b u t e df r o mt h eE Rl u m e nt ot h en u c l e a r
envelope (NE) [29]. These cells also display abnormal
morphology and thickening of the NE, including
altered connections between the inner and outer
membranes, and generation of whorled membrane
inclusions that appear to ‘spin off’ the ER and NE. These
inclusions are associated with the vesicular monoamine
transporter VMAT2, a finding that might functionally
relate TorsinA to the dopaminergic system [30]. In
addition, TorsinA has been found to regulate cellular
trafficking of the dopamine transporter and other
membrane-bound proteins. It has also been shown
that the mutant TorsinA interferes with cytoskeletal
events that may affect the development of neuronal
pathways in the brain and that it is prematurely
degraded by both the proteasome and macroautophagy
pathways [31].
THAP1, instead, is a member of a family of cellular
f a c t o r ss h a r i n gah i g h l yc o n s e r v e dD N A - b i n d i n gT H A P
domain, which is an atypical zinc finger, and can
regulate endothelial cell proliferation. A proposed
disease mechanism is that DYT6 mutations may
disrupt THAP1 binding to DNA and produce transcrip-
tional dysregulation. Although the mechanism under-
lying dysfunction of the THAP1 protein in DYT6
dystonia is not known in the same detail as that of
TorsinA, these two genetic disorders are capable of
producing comparable motor abnormalities that likely
underlie a similar disruption of communication within
the basal ganglia. The availability of a second PTD gene
will provide new insights into the pathophysiology of
this very peculiar movement disorder and allow
investigators to perform comparative functional stu-
dies to identify shared pathways leading to the
development of dystonia. In particular, we expect
that functional imaging studies will be able to further
identify shared as well as different patterns of activa-
tion/deactivation of brain areas in patients with DYT1
and DYT6 dystonia, highlighting their specific role in
the pathogenesis of these forms of PTD. There is great
need for specific molecular models which could
explain the underlying pathogenetic mechanisms
shared by different genetic forms.
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